Feed PRNAF
PR

Alterity Therapeutics Limited

PRNAF · OTC

$0.06 +0.00% (+$0.00)
Market Cap $17.3M
P/E Ratio -
Div. Yield -
ROE 141.08%
Piotroski F-Score Weak
3/9
Valuation
85 /100
Cheap
P/S 2.30x
P/B 0.41x
P/E N/A
Growth
100 /100
Growing
Book val. growth 29.32%
EPS growth N/A
FCF growth N/A
Profitability
20 /100
Weak
Gross margin 95.89%
FCF margin 265.48%
Net margin 381.67%
Quality
2 /100
Poor
ROIC 72.18%
Asset turnover 0.16x
ROE 141.08%
Debt
94 /100
Low
Debt/Equity 0.00x
Net debt/EBITDA 1.08x
Current ratio 12.98x
Stability
49 /100
Moderate
Beta -0.04x
Profitable years 0
EPS volatility 27.78%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about PRNAF
Online

Sector

Healthcare

Industry

Biotechnology

CEO

David A. Stamler

Employees

11

Headquarters

Melbourne

Upcoming events

04 MAR

Earnings

Upcoming earnings report

173d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.